Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Digestive System Diseases

Nervous System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Breast Neoplasms

Melanoma

Head and Neck Neoplasms

Gastrointestinal Neoplasms

Central Nervous System Neoplasms

Thoracic Neoplasms

Urogenital Neoplasms

Digestive System Neoplasms

Skin Diseases

Breast Diseases

Gastrointestinal Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Patients will receive alisertib orally twice a day for the first 7 days of a 21 day cycle. Patients will also receive pazopanib orally once a day continuously. Treatment continues until disease progression, unacceptable toxicity or patient refusal. The study consists of two components which are the dose finding component and optimally tolerated dose extension with pharmacokinetics component.

Alisertib at the assigned dose by mouth (PO) twice a day for 7 days beginning on day 1 of a 21 day cycle.

Alisertib

Pazopanib at the assigned dose once a day continuously for the duration of treatment.

Pazopanib

Arkadiusz Z. Dudek, M.D.

This phase I trial using the EffTox design will evaluate activity and safety of alisertib, an Aurora A kinase inhibitor, when given in combination with the selective VEGFR inhibitor pazopanib in patients with advanced, previously treated non-hematologic solid tumors.

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

STM-01: Phase I EffTox Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors

Complete all planned treatment for cycle 1 (defined as 14 doses of alisertib and daily pazopanib) without dose limiting toxicity and are able to start cycle 2 with no more than a 2 week delay.

Adverse events which occur after taking at least one dose of study treatment with either alisertib and/or pazopanib.

Millennium Pharmaceuticals, Inc.

University of Illinois at Chicago

Professor

Spots Global Cancer Trial Database for genitourinary neoplasms malignancy and gender unspecified